雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Frontiers of Muscle Science. Advances in genome editing technologies for treating muscular dystrophy. Makita Yukimasa 1 , Hozumi Hiroyuki 1 , Hotta Akitsu 2 1Takeda pharmaceutical company Limited, Japan. 2Center for iPS Cell Research and Application, Kyoto University, Japan. pp.391-399
Published Date 2017/2/28
DOI https://doi.org/10.20837/4201703067
  • Abstract
  • Look Inside
  • Reference

 Recent advances in genome editing technologies have opened the possibility for treating genetic diseases, such as Duchenne muscular dystrophy(DMD), by correcting the causing gene mutations in dystrophin gene. In fact, there are several reports that demonstrated the restoration of the mutated dystrophin gene in DMD patient-derived iPS cell or functional recovery of forelimb grip strength in DMD model mice. For future clinical applications, there are several aspects that need to be taken into consideration:efficient delivery of the genome editing components, risk of off-target mutagenesis and immunogenicity against genome editing enzyme. In this review, we summarize the current status and future prospective of the research in applying genome editing technologies to DMD.



基本情報

電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社

関連文献

もっと見る

文献を共有